We prioritise research into vaccines and medicines across our four core therapeutic areas of infectious diseases, HIV, respiratory/immunology, and oncology. We continue to strengthen our pipeline of vaccines and medicines, applying our growing expertise and partnerships in technology and data to increase the productivity of our R&D.
What are they working on?
In 2023, we invested £6.2 billion in R&D to enhance our pipeline of vaccines and medicines and help us get ahead of disease together. Our scientists prioritise genetically identified targets that are at least twice as likely to succeed in the clinic. They also prioritise infectious disease targets and immune-modulators that have greater lifecycle opportunities.
There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
